Literature DB >> 12042810

Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus.

Corina M Borza1, Lindsey M Hutt-Fletcher.   

Abstract

Epstein-Barr virus is ubiquitous and is causally implicated in lymphoid and epithelial malignancies. Virus invades oropharyngeal mucosa and establishes latency in B lymphocytes. Reactivating lymphocytes shed virus into saliva for spread to new hosts. A complex of three virus glycoproteins, gH, gL and gp42, is essential for entry. B-cell entry requires binding of gp42 to human leukocyte antigen (HLA) class II whereas entry into epithelial cells lacking HLA class II requires complexes without gp42. To accommodate infection of each, the virus carries both three-part and two-part complexes. We show here that HLA class II in the virus-producing cell alters the ratio of three-part to two-part complexes. As a consequence, virus originating in epithelial cells efficiently infects B cells whereas B-cell derived virus better infects epithelial cells. This molecular switch is a novel strategy that could alter tropism of virus from epithelium to B cells and then back to epithelium in a new host.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042810     DOI: 10.1038/nm0602-594

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  211 in total

1.  B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression.

Authors:  Barbro Ehlin-Henriksson; John Gordon; George Klein
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

2.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

3.  A case of Epstein-Barr Virus (EBV)-associated thymic carcinoid and investigation of existence of EBV-infected cells in thymus and thymic tumors.

Authors:  Hiroaki Takeuchi; Hiroshi Fujita; Fumio Iwasaki; Takako Takeuchi; Ken-Ichi Imadome; Toshika Okumiya; Tomohiro Matsui; Mutsuo Takahashi
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

Review 4.  Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years.

Authors:  Ralf D Hess
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  Modeling the dynamics of virus shedding into the saliva of Epstein-Barr virus positive individuals.

Authors:  Giao T Huynh; Libin Rong
Journal:  J Theor Biol       Date:  2012-06-07       Impact factor: 2.691

6.  Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex.

Authors:  Hisae Matsuura; Austin N Kirschner; Richard Longnecker; Theodore S Jardetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

Review 7.  Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection.

Authors:  Lindsey M Hutt-Fletcher; Liudmila S Chesnokova
Journal:  Virulence       Date:  2010 Sep-Oct       Impact factor: 5.882

Review 8.  Herpesvirus transport to the nervous system and back again.

Authors:  Gregory Smith
Journal:  Annu Rev Microbiol       Date:  2012-06-15       Impact factor: 15.500

9.  Nucleophosmin contributes to the transcriptional activation function of the Epstein-Barr virus EBNA1 protein.

Authors:  Natasha Malik-Soni; Lori Frappier
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

10.  Epstein-Barr virus associated peri-implantitis: a split-mouth study.

Authors:  Fernando Verdugo; Ana Castillo; Francisca Castillo; Agurne Uribarri
Journal:  Clin Oral Investig       Date:  2014-05-07       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.